Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9215MR)

This product GTTS-WQ9215MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ9215MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11466MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ4292MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ10892MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ10394MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ10938MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MBG-453
GTTS-WQ1707MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ3165MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ3217MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ARGX-110
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW